Mannheimer Swartling has advised on Vimian’s issuance of senior unsecured bonds and the entering into of a new revolving credit facility
The credit facility and the proceeds from the bonds will be used, inter alia, to refinance Vimian’s existing facilities agreement, as well as for general corporate purposes. The bonds have a tenor of three years and were issued with a coupon of EURIBOR 3m plus 200 basis points. DNB Carnegie Investment Bank AB (publ), Nordea Bank Abp, and Skandinaviska Enskilda Banken AB (publ) acted as joint bookrunners in connection with the bond issuance. The credit facility, arranged by DNB Bank ASA, Sweden Branch, Nordea Bank Abp, filial i Sverige and Skandinaviska Enskilda Banken AB (publ), consists of a multicurrency revolving credit facility of EUR 330,000,000 (with an uncommitted incremental facility of up to EUR 100 million).
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. Vimian’s shares are listed on Nasdaq Stockholm.
Mannheimer Swartling advised the joint bookrunners and the bank syndicate in the transaction.
